Results 51 to 60 of about 8,310 (206)

Prescribing of medication to prevent glucocorticoid harms in patients with Polymyalgia Rheumatica: a cross‐sectional study and two emulated target trials in the Clinical Practice Research Datalink Aurum

Arthritis &Rheumatology, Accepted Article.
Objectives Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐ and gastro‐protective medications are recommended for those at high‐risk of adverse events from GCs but no trials have evaluated their effectiveness in PMR.
Helen Twohig, David Jenkinson, James Bailey, Samantha Hider, Ian C Scott, Sara Muller   +5 more
wiley   +1 more source

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: an experimental study in the rat [PDF]

, 2018
OBJECTIVES: Pathogenesis of bisphosphonate-related osteonecrosis of the jaws (BRONJ) is not fully explained. An antiangiogenic effect of bisphosphonates (BPs) or an altered bone quality have been advocated.
D. Chappard, F. Pascaretti-Grizon, G. Mabilleau, H. Marchand-Libouban, J.D. Kün-Darbois   +4 more
core   +1 more source

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Frontiers in Oral Health
IntroductionMedication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone.
Rodolfo Mauceri, Rodolfo Mauceri, Sonia Arduini, Martina Coppini, Martina Coppini, Martina Coppini, Monica Bazzano, Isabel Trujillo, Giuseppina Campisi   +8 more
doaj   +1 more source

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review

Journal of Research in Medical Sciences, 2021
Medication related osteonecrosis of the jaw (MRONJ) is a severe condition affecting the jaws of patients exposed to specific drugs, and is primarily described in patients receiving bisphosphonate (BP) therapy.
Roberto Sacco, Julian Woolley, Julian Yates, Monica Diuana Calasans-Maia, Oladapo Akintola, Vinod Patel   +5 more
doaj   +1 more source

Pathogenesis and potential therapeutic targets of trichorhinophalangeal syndrome; lessons obtained from animal studies

Developmental Dynamics, EarlyView.
Abstract Trichorhinophalangeal syndrome (TRPS) is a rare genetic disease inherited in an autosomal dominant manner. It occurs in 1 in 100,000 people globally and is caused by several types of mutations of the TRPS1 gene. Since the first human patient was reported in 1966, typical and atypical pathologies, disease courses, and treatment case ...
Naoya Saeki, Rinna Kanai, Sayuri Tatsuta, Shinichi Kawaguchi, Masatsune Itoh, Shinsuke Ohba, Makoto Abe   +6 more
wiley   +1 more source

Fluorescent risedronate analogue 800CW-pRIS improves tooth extraction-associated abnormal wound healing in zoledronate-treated mice

Communications Medicine, 2022
Okawa et al. evaluate a fluorescent risedronate analogue, 800CW-pRIS, as a potential treatment for medication-related osteonecrosis of the jaw. The authors demonstrate an improvement in wound healing and inflammation with 800CW-pRIS pre-treatment in a ...
Hiroko Okawa, Takeru Kondo, Akishige Hokugo, Philip Cherian, Oskar Sundberg, Jesus J. Campagna, Boris A. Kashemirov, Varghese John, Shuting Sun, Frank H. Ebetino, Charles E. McKenna, Ichiro Nishimura   +11 more
doaj   +1 more source

MicroRNA in medication related osteonecrosis of the jaw: a review

Frontiers in Physiology, 2023
Medication related osteonecrosis of the jaw (MRONJ) is a condition caused by inhibition of the osteoclast activity by the anti-resorptive and anti-angiogenic drugs.
Siti Salmiah Mohd Yunus, Hui Yuh Soh, Mariati Abdul Rahman, Xin Peng, Chuanbin Guo, Roszalina Ramli   +5 more
doaj   +1 more source

Perioperative Piperacillin/Tazobactam Reduces Early Onset SSI in Preirradiated Patients Undergoing Microvascular Head and Neck Reconstruction

Head &Neck, EarlyView.
ABSTRACT Background Preirradiated patients undergoing microvascular head and neck reconstruction for tumor recurrence or osteoradionecrosis (ORN) face surgical site infection (SSI) rates exceeding 30%. The impact of perioperative extended‐spectrum antibiotic coverage remains unclear. This study hypothesizes that calculated prophylaxis with piperacillin/
Johannes G. Schuderer, Florian Hoferer, Jonas Eichberger, Mathias Fiedler, André Gessner, Stilla Bauernfeind, Maximilian Gottsauner, Felix Nieberle, Michael Maurer, Johannes K. Meier, Torsten E. Reichert, Tobias Ettl   +11 more
wiley   +1 more source

Immune Dysfunction in Medication-Related Osteonecrosis of the Jaw

International Journal of Molecular Sciences, 2023
The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) is multifactorial and there is a substantial consensus on the role of antiresorptive drugs (ARDs), including bisphosphonates (BPs) and denosumab (Dmab), as one of the main determinants.
Ilaria Roato, Rodolfo Mauceri, Vincenzo Notaro, Tullio Genova, Vittorio Fusco, Federico Mussano   +5 more
openaire   +3 more sources